Our Pipeline
Utilizing Our Proprietary Technologies to Create Life-Changing Therapies
Internal Development Programs
| Program | Indication | Preclinical | IND Enabling | Phase 1 | Phase 2 | Highlights |
| SYSTEMIC DNASE I + CHEMO | Pancreatic Carcinoma |
Preclinical Phase complete
|
IND Enabling Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Upcoming study to evaluate combination with chemo |
| SYSTEMIC DNASE I + ICIs | Solid Tumors |
Preclinical Phase complete
|
IND Enabling Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Upcoming study to evaluate combination with immune checkpoint inhibitors |
| SYSTEMIC DNASE I + CAR T | Solid Tumors |
Preclinical Phase in progress
|
IND Enabling Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Potential to enhance CAR T cell function in the tumor microenvironment |
| DNASE-ARMORED CAR T | Solid Tumors |
Preclinical Phase in progress
|
IND Enabling Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Potential to enhance CAR T cell function in the tumor microenvironment |
| XCART™ PLATFORM | B-Cell Non-Hodgkin Lymphoma |
Preclinical Phase in progress
|
IND Enabling Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Patient and tumor-specific cell therapy approach |
Receiving royalties on net sales through license agreement in the field of coagulation disorders
| Program | Indication | Partners | |
| POLYXEN® | Next Generation Half-Life Extension Platform Technology | Undisclosed | Receiving royalties on net sales through exclusive license agreement in the field of coagulation disorders |
| EREPOXEN (PSA-EPO) | Treatment of anemia in patients with chronic kidney disease (CKD) |
 |
Partner filed registration dossier in Russia |